Filtered By:
Management: WHO
This page shows you your search results in order of relevance. This is page number 17.
Order by Relevance | Date
Total 30183 results found since Jan 2013.
Propionyl-L-carnitine for intermittent claudication
CONCLUSIONS: When PLC was compared with placebo, improvement in walking distance was mild to moderate and safety profiles were similar, with moderate overall certainty of evidence. Although In clinical practice, PLC might be considered as an alternative or an adjuvant to standard treatment when such therapies are found to be contraindicated or ineffective, we found no RCT evidence comparing PLC with standard treatment to directly support such use.PMID:34954832 | DOI:10.1002/14651858.CD010117.pub2
Source: Cochrane Database of Systematic Reviews - December 26, 2021 Category: General Medicine Authors: Victor Kamoen Robert Vander Stichele Laurence Campens Dirk De Bacquer Luc Van Bortel Tine Lm de Backer Source Type: research
Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism
CONCLUSIONS: Evidence suggests that combining IPC with pharmacological prophylaxis, compared to IPC alone reduces the incidence of both PE and DVT (low-certainty evidence). Combining IPC with pharmacological prophylaxis, compared to pharmacological prophylaxis alone, reduces the incidence of both PE (low-certainty evidence) and DVT (high-certainty evidence). We downgraded due to risk of bias in study methodology and imprecision. Very low-certainty evidence suggests that the addition of pharmacological prophylaxis to IPC increased the risk of bleeding compared to IPC alone, a side effect not observed when IPC is added to ph...
Source: Cochrane Database of Systematic Reviews - January 28, 2022 Category: General Medicine Authors: Stavros Kakkos George Kirkilesis Joseph A Caprini George Geroulakos Andrew Nicolaides Gerard Stansby Daniel J Reddy Source Type: research
Angioplasty versus stenting for subclavian artery stenosis
CONCLUSIONS: There is currently insufficient evidence to determine whether stenting is more effective than angioplasty alone for stenosis of the subclavian artery.PMID:35187653 | DOI:10.1002/14651858.CD008461.pub4
Source: Cochrane Database of Systematic Reviews - February 21, 2022 Category: General Medicine Authors: Wagner Iared Jos é Eduardo Mourão Andrea Puchnick Fernando Soma David Carlos Shigueoka Source Type: research
The Lancet publishes studies showing Roche ’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months
Two papers in The Lancet highlight one-year results from Roche ’s phase III trials evaluatingfaricimab inneovascular or “wet” age-related macular (nAMD) and diabetic macular edema (DME)Across four studies, about half of eligiblefaricimab patients were able to go four months between treatments, and approximately three-quarters could be treated every three months or longerReductions in central subfield thickness (CST) and resolution ofintraretinal fluid consistentlyfavouredfaricimab overaflibercept in DME, and meaningful and comparable CST reductions were seen innAMD in the first yearBasel, 24 January 2022 - Roche (SIX...
Source: Roche Media News - January 24, 2022 Category: Pharmaceuticals Source Type: news
Angioplasty versus stenting for subclavian artery stenosis
CONCLUSIONS: There is currently insufficient evidence to determine whether stenting is more effective than angioplasty alone for stenosis of the subclavian artery.PMID:35187653 | DOI:10.1002/14651858.CD008461.pub4
Source: Cochrane Database of Systematic Reviews - February 21, 2022 Category: General Medicine Authors: Wagner Iared Jos é Eduardo Mourão Andrea Puchnick Fernando Soma David Carlos Shigueoka Source Type: research
Antiplatelet agents for the treatment of deep venous thrombosis
CONCLUSIONS: In chronic DVT settings, following the initial standard treatment with anticoagulants, there is low-certainty evidence that antiplatelet agents in addition to BMP may reduce recurrent VTE, (NNTB = 14) when compared to BMP plus placebo. Moderate-certainty evidence shows no clear difference in adverse events, major bleeding and PE when antiplatelet agents are used in addition to BMP compared to BMP plus placebo. In acute and chronic DVT settings, following the initial standard treatment with anticoagulants, we can draw no conclusions for antiplatelet agents in addition to BMP compared to BMP alone due to very lo...
Source: Cochrane Database of Systematic Reviews - July 25, 2022 Category: General Medicine Authors: Carolina Dq Flumignan Luis Cu Nakano Jose Cc Baptista-Silva Ronald Lg Flumignan Source Type: research
Weekly Overseas Health IT Links – 15th October, 2022.
This article uses the one that divides providers into groups depending on the life cycle stage the clinic is at the given moment. According to this classification, medical providers fall into three groups:BeginnersGrowing clinicsWell-established providersHealth care providers are business entities, so their life cycle, like that of any business, consists of the early stage or launch, growth and maturity. At each stage, providers have different priorities and goals, and the choice of medical software solutions should be made accordingly.Medical software for beginnersThe launch phase can be tough. At this stage, the profits ...
Source: Australian Health Information Technology - October 15, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs
Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis
CONCLUSIONS: The current review suggests that DOACs may be superior to conventional therapy in terms of safety (major bleeding), and are probably equivalent in terms of efficacy. There is probably little or no difference between DOACs and conventional anticoagulation in the prevention of recurrent VTE, recurrent DVT, pulmonary embolism and all-cause mortality. DOACs reduced the rate of major bleeding compared to conventional anticoagulation. The certainty of evidence was moderate or high.PMID:37058421 | DOI:10.1002/14651858.CD010956.pub3
Source: Cochrane Database of Systematic Reviews - April 14, 2023 Category: General Medicine Authors: Xiaoqin Wang Yanfang Ma Xu Hui Meixuan Li Jing Li Jinhui Tian Qi Wang Peijing Yan Jianfeng Li Ping Xie Kehu Yang Liang Yao Source Type: research
